Clinical trial
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
NCT00892931 is registered in ClinicalTrials.gov with Myrexis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
- Lead sponsor
- Myrexis Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- September 30, 2011
- Enrollment
- 56 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
glioblastoma multiforme